1 Here,
we have used a (89)Zr-radiolabeled human CD8-specific minibod
2 Here,
we have used a combination of immunological assays, structura
3 Here,
we have used a highly biologically replicated whole transcrip
4 We have used a novel platform that integrates a bone marrow-d
5 Here,
we have used a technology originally developed for mRNA in vi
6 We have used an integrated approach to discover placental gen
7 Here,
we have used chick neural crest (NC) cells, a highly migrator
8 Here,
we have used Cre-recombinase-mediated genetic labeling to ide
9 We have used cytotoxicity assays and a variety of biophysical
10 Furthermore,
we have used different approaches to analyze the differences
11 We have used electron microscopic connectomics techniques, op
12 We have used filtering criteria based on cellular location an
13 Here,
we have used genomic and transcriptomic analysis to identify
14 Here
we have used genotyping by sequencing (GBS) to determine the
15 better understand the biology underpinning such treatments,
we have used gnotobiotic mice to model microbiota manipulatio
16 We have used high-speed atomic force microscopy (HS-AFM) and
17 In addition,
we have used highly selective HDAC11 inhibitors that not only
18 Furthermore,
we have used immunoprecipitation and Western blotting to show
19 In conclusion,
we have used in vitro human culture systems and CyTOF to defi
20 We have used magnetization transfer NMR experiments to measur
21 We have used multi-year field experiments to examine the phys
22 nderstand the early stages of the amyloid assembly process,
we have used native electrospray ionization (ESI) together wi
23 We have used nested validation to develop models and further
24 We have used novel rapid methods to structurally characterize
25 To explore this issue further,
we have used one such organism, the green alga Chlamydomonas
26 In this work,
we have used open-shell dispersion-corrected DFT calculations
27 Herein,
we have used Pseudomonas protegens Pf-5 as a model to elucida
28 In this study,
we have used rHLA-DRB1*01:01 and HLA-DRB1*03:01 molecules to
29 In this study
we have used RNAi technology to show, for the first time, tha
30 We have used single and multi-bunch, X-ray imaging to differe
31 Here
we have used single molecule fluorescence resonance energy tr
32 To identify genes that control hypothalamic development,
we have used single-cell RNA sequencing (scRNA-Seq) to profil
33 In this study,
we have used Sinomenine (Sino), a potent anti-inflammatory an
34 Herein,
we have used structure-guided computational screening and opt
35 To demonstrate the feasibility of this approach,
we have used the antihistamine agent loratadine (1).
36 Here,
we have used the chemical modification of Trp9, site-directed
37 In the present study, for the first time,
we have used the idea of synergic control and the framework o
38 To address this limitation,
we have used the light-inducible GAVPO transactivator in comb
39 We have used the model to generate district-level maps for th
40 In previous studies,
we have used these data to uncover novel regulatory signals a
41 Finally,
we have used these validated computational models to establis
42 As a proof of concept,
we have used this CRISPR-E test in the model organism Dictyos
43 We have used this key fossil taxon to investigate the evoluti
44 Here,
we have used time-resolved fluorescence resonance energy tran
45 formation of a structural systems biology framework, which
we have used to analyze differences between the reactive oxyg
46 Here,
we have used TT-seq and mNET-seq to monitor the direct effect
47 To address this,
we have used two experimental models, administering alpha-nap
48 We have used two-dimensional quantitative NMR to determine se
49 the ambiguity surrounding class A beta-lactamase catalysis,
we have used ultrahigh-resolution X-ray crystallography and t
50 Here,
we have used yeast-two-hybrid screening to identify OsPIP5K1,